Nonopioid Pain Management

Research presented at AMCP Nexus 2024 underscored and explored the need for treatments that can prevent or mitigate flare-ups in patients with AD.

New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.

Multimodal analgesia provides more effective pain management—and leads to a decrease in opioid use.

Suzetrigine could represent the first new nonopioid drug in a distinct class of pain medications in approximately 20 years.

Acupuncture, a practice with thousands of years of history, has become increasingly accepted in mainstream medicine.

Research is limited on the effectiveness and efficacy of this class of medications.

Patients with chronic migraine can frequently overuse acute medications, leading to medication overuse headaches.

Whether patients present with complaints of an aching muscle from a workout or a sudden twinge in the back, consider recommending these topical analgesics.

Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.

Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.

Researchers conducted a meta-analysis and systematic review to determine the efficacy of using antidepressants to treat older adults for knee osteoarthritis pain.

“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.

Mark Garofoli combined personal anecdotes with professional expertise to deliver a compelling presentation on kidney stone pain at this year’s PAINWeek National Conference.

“Reducing abdominal adiposity may be considered a target for chronic pain management, particularly in those with pain in multiple sites and widespread pain,” wrote investigators.

Click Therapeutics announced that CT-132 met its primary endpoint in the phase 3 ReMMi-D trial.

The investigational oral, selective NaV1.8 pain signal inhibitor from Vertex Pharmaceuticals demonstrated a favorable benefit/risk profile in 3 phase 3 trials.

With growing concerns around opioid use disorder, interventional pain management for patients with cancer can provide effective relief without the side effects associated with medication.

Complementary health approaches, like yoga or acupuncture, can be particularly appealing to patients seeking natural and non-invasive approaches to improve their health.

Vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate for children who experience migraine attacks, showed a study conducted in Saudi Arabia.

The number of digital therapeutics available for migraine is likely to expand.